Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects

AIDS Research and Human Retroviruses

Volumn 15, Issue 12, 1999, Pages 1047-1052

  Noormohamed, Faruq H ^a   Youle, Michael S ^b   Higgs, Christopher J ^c   Kook, Karin A ^d   Hawkins, David A ^c   Lant, Ariel F ^a   Thomas, Steven D ^e  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d Salamandra LLC   (United States)

^e CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; COTRIMOXAZOLE; DIDANOSINE; LAMIVUDINE; STAVUDINE; THALIDOMIDE; VALACICLOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DISTRIBUTION VOLUME; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; HEADACHE; HEART RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; VERTIGO;

ADMINISTRATION, ORAL; ADULT; BLOOD PRESSURE; CROSS-OVER STUDIES; HALF-LIFE; HEART RATE; HIV INFECTIONS; HUMANS; MALE; THALIDOMIDE;

EID: 0033543118     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310331     Document Type: Article

References (30)

1. Sheskin J: The treatment of lepra reaction in lepromatosis: Fifteen years experience with thalidomide. Int J Dermatol 1980;19: 318-322.
2. Sampaio EP, Kaplan G, Miranda A, et al.: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993;168:408-414.
3. Hamuryudan V, Mat C, Saip S, et al.: Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomised, double blind, placebo controlled trial. Ann Intern Med 1998;128:443-450.
4. Londono F: Thalidomide in the treatment of actinic prurigo. Int J Dermatol 1973;12:326-328.
5. Lovell CR, Hawk JLM, Canlan CD, et al.: Thalidomide and actinic prurigo. Br J Dermatol 1983;108:467-471.
6. Grosshans E and Illy G: Thalidomide therapy for inflammatory dermatosis. Int J Dermatol 1984;23:598-602.
7. Bessis D, Guillot B, and Montpont S: Thalidomide for systemic lupus erythematosus. Lancet 1992;339:549-550.
8. Vogeslang GB, Farmer ER, Hess AD, et al.: Thalidomide for treatment of graft-versus-host disease. New Engl J Med 1992;326: 1055-1058.
9. Heney D, Norfolk R, and Wheeldon J: Thalidomide treatment for chronic graft-versus-host disease. Br J Haematol 1991;78:23-27.
10. Youle M, Clarbour J, Farthing C, et al.: Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Br Med J 1989;298:432.
11. Alexander LN and Wilcox CMA: Prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. AIDS Res Hum Retroviruses 1997;13:301-304.
12. Jacobson JM, Greenspan JS, Spritzler J, et al.: Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997;336:1487-1493.
13. Sharpstone D, Rowbottom A, Francis N, et al.: Thalidomide: A novel therapy for microsporidiosis. Gastroenterology 1997;112: 1823-1829.
14. Haslett P, Hampstead M, Seidman C, et al.: The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 1997;13:1047-1054.
15. Tramontana JM, Utaipat U, Molloy A, et al.: Thalidomide treatment reduces tumor necroses factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:348-397.
16. Gunzler V: Thalidomide in human immunodeficiency virus (HIV) patients. Drug Safety 1992;7:116-134.
17. McBride WG: Thalidomide and congenital abnormalities. Lancet 1991;2:1358.
18. Schumacher H, Smith RL, and Williams RT: The metabolism of thalidomide: Spontaneous hydrolysis of thalidomide in solution. Br J Pharmacol 1965;25:324-337.
19. Eriksson T, Bjorkman S, Fyge A, and Ekberg H: Determination of thalidomide in plasma and blood by high performance liquid chromatography: Avoiding hydrolytic degradation. J Chromatogr 1992; 582:211-216.
20. Schumacher HJ, Wilson JG, Terapane JF, and Rosedale SL: Thalidomide: Disposition in rhesus monkey and studies of its hydrolysis in tissues of this and other species. J Pharmacol Exp Ther 1970;173:265-269.
21. Chen T, Vogelslang GB, Petty BG, et al.: Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos 1989;17:402-405.
22. Huupponen R and Pyykko K: Stability of thalidomide in human plasma. Clin Chem 1995;41:1199.
23. Midha KK, Ormsby ED, Hubbard JW, et al.: Logarithmic transformation in bioequivalence: Application with two formulations of perphenazine. J Pharm Sci 1993;82:138-144.
24. Piscitelli SC, Figg WD, Hahn B, et al.: Single dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1997;41:2797-2799.
25. Donahue SR, Collins JM, Flockhart DA, et al.: Thalidomide pharmacokinetics do not change with chronic administration. Clin Pharm Ther 1997;62:236. [Abstract]
26. Boughton BJ, Sheehan TMT, Wood T, et al.: High performance liquid chromatographic assay of plasma thalidomide: Stabilization of specimens and determination of tentative therapeutic range for chronic graft-versus-host disease. Ann Clin Biochem 1995;32: 79-83.
27. Figg WD, Raje S, Bauer KS, et al.: Pharmacokinetics of thalidomide in an elderly prostrate cancer population. J Pharm Sci 1999;88:121-125.
28. Hess CW, Hunzicker T, Kupfer A, and Ludin HP: Thalidomide-induced peripheral neuropathy: A prospective clinical, neurophysiological and pharmacogenetic evaluation. J Neurol 1986; 233:83-89.
29. Muller GW, Corral LG, Shire MG, et al.: Structure modifications of thalidomide produce analogues with enhanced tumor necrosis factor inhibitory activity. J Med Chem 1996;39:3238-3240.
30. Teubert U, Zwingenberger K, Wnendt S, and Eger K: 5′-Substituted thalidomide analogues as modulators of TNF-α. Arch Pharmazie 1998;331:7-12.